

CERTIFICATE

Survey of 20 May 2022

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 23 - Rivaroxaban (503):

Validity 12 months:

Rivaroxaban

(R) analysis is subject to the RiliBÄK

Participant:
2430
MUDr. Martin Spacek, PhD.
Vseobecna fakultni nemocnice v Praze
Centralni hematologicke laboratore ULBLD
U Nemocnice 2
12808 Praha 2

Düsseldorf, 14 July 2022



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 20 May 2022

You have participated in the External Quality Assessment with the following analysis


Haemostasis 23 - Rivaroxaban (503):

Rivaroxaban

(R) analysis is subject to the RiliBÄK

Participant:
2430
MUDr. Martin Spacek, PhD.
Vseobecna fakultni nemocnice v Praze
Centralni hematologicke laboratore ULBLD
U Nemocnice 2
12808 Praha 2

Düsseldorf, 14 July 2022



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz
(Adviser)